What's the actual difference between 503A and 503B?

503A pharmacies dispense patient-specific prescriptions to a named patient. 503B outsourcing facilities can produce office-stock that a clinic dispenses to multiple patients, but must follow cGMP and the FDA bulks list.

Can my clinic keep peptides in office for in-clinic injection?

Only when sourced from a 503B facility for substances on the 503B bulks list, or under a patient-specific 503A prescription. Pulling from a 503A patient-named vial for another patient is a violation.

Why are most peptides only available 503A?

503B has a much shorter approved bulks list. Most peptides (BPC-157, TB-500, ipamorelin, sermorelin, etc.) flow through 503A pharmacies with patient-specific prescriptions.

Does Direct Peptide Sales handle the 503A vs 503B routing?

Yes. We route each product to the correct pharmacy type, your providers prescribe under their license, and every order ships with a COA and chain-of-custody documentation.

What's the actual difference between 503A and 503B?

503A pharmacies dispense patient-specific prescriptions to a named patient. 503B outsourcing facilities can produce office-stock that a clinic dispenses to multiple patients, but must follow cGMP and the FDA bulks list.

Can my clinic keep peptides in office for in-clinic injection?

Only when sourced from a 503B facility for substances on the 503B bulks list, or under a patient-specific 503A prescription. Pulling from a 503A patient-named vial for another patient is a violation.

Why are most peptides only available 503A?

503B has a much shorter approved bulks list. Most peptides (BPC-157, TB-500, ipamorelin, sermorelin, etc.) flow through 503A pharmacies with patient-specific prescriptions.

Does Direct Peptide Sales handle the 503A vs 503B routing?

Yes. We route each product to the correct pharmacy type, your providers prescribe under their license, and every order ships with a COA and chain-of-custody documentation.

What exactly does Direct Peptide Sales do?

We are a referral and introduction service. We verify your business and the states it serves, then introduce you to licensed telehealth prescribers and 503A or 503B pharmacies. You contract directly with them. We do not sell, price, prescribe, compound, bill, or ship any product.

How fast can my practice be introduced to a source?

Timing depends on your business details, states served, and partner fit. DPS does not guarantee an introduction or launch date. The independent partners determine their own onboarding requirements.

Nothing to apply, and we do not charge practices a fee. Product pricing, account terms, and any minimums are set by the pharmacy or prescriber you contract with, not by us.

Where do the peptides come from and are they verified?

Ask the independent pharmacy to confirm current product status, applicable licenses, and preparation-specific quality documentation. DPS does not test or certify products. The COA library contains illustrative examples, not proof for a future lot.

Who handles prescribing, billing, and shipping?

The licensed prescriber and the pharmacy do. Prescribing is the provider's independent clinical decision, and dispensing, billing, and shipping sit with the pharmacy. We are not part of that transaction.

What if I'm not a licensed clinic?

Non-licensed wellness businesses such as coaches, gyms, studios, and nutrition practices can be introduced to a licensed telehealth prescriber who owns the clinical relationship. You never prescribe, hold, or dispense product.

How do you vet the sources you introduce?

Before contracting, independently verify the source legal identity, licenses for the relevant states, preparation-specific documentation, and written responsibilities. A facility license or COA does not establish that every proposed product may lawfully be prescribed or supplied.

Which states do you serve?

Coverage depends on the states your business serves and the independent partners' licenses. An introduction is not authorization to prescribe or ship into a state.

Compliance

503A vs 503B compounding: which one your program needs

If you're launching a peptide or GLP-1 program you need to know which pharmacy type can supply which product, and when. Get this wrong and you risk patient harm, state board action, and FDA enforcement.

Direct Peptide Sales is a referral service for licensed practices and wellness businesses. We introduce you to licensed prescribers and 503A/503B pharmacies. We do not sell, prescribe, bill, or ship product.

Last reviewed September 2, 2026 · Editorial policy

503A: patient-specific compounding

A 503A pharmacy fills prescriptions for a named patient. Most peptides flow through 503A because they aren't on the 503B bulks list.

Prescription must name a specific patient
Cannot be dispensed to other patients
Wider formulary, including most research peptides
Regulated primarily by state boards of pharmacy

503B: outsourcing facility for office stock

A 503B facility registers with the FDA, follows cGMP, and can supply office-stock substances on the FDA bulks list. Practical for high-volume GLP-1 programs.

Allowed to ship without patient names for in-office use
Limited to FDA-approved bulks list
cGMP manufacturing standards
FDA-inspected facility

Common mistakes that trigger enforcement

Most clinic problems come from mixing the two models or pulling product across patient lines.

Using a 503A patient-named vial for a different patient
Holding office stock of non-bulks-list peptides
Marketing compounded products as equivalent to FDA-approved
Bulk-buying peptides without a patient prescription chain

How Direct Peptide Sales structures pharmacy routing

Every order is automatically routed to the correct pharmacy type based on the product, the dosing model, and your state's rules.

Peptide therapy (BPC-157, TB-500, ipamorelin): 503A patient-specific
GLP-1 cash-pay programs: 503A or 503B based on volume
In-office injectable B12/lipo: 503B office stock
Documentation, COAs, and patient records preserved end-to-end

What you take home

If you only remember three things: 503A is for individual patients, 503B is for office stock from a short approved list, and crossing the streams is the fastest way to lose your program.

Frequently asked questions

What's the actual difference between 503A and 503B?: 503A pharmacies dispense patient-specific prescriptions to a named patient. 503B outsourcing facilities can produce office-stock that a clinic dispenses to multiple patients, but must follow cGMP and the FDA bulks list.
Can my clinic keep peptides in office for in-clinic injection?: Only when sourced from a 503B facility for substances on the 503B bulks list, or under a patient-specific 503A prescription. Pulling from a 503A patient-named vial for another patient is a violation.
Why are most peptides only available 503A?: 503B has a much shorter approved bulks list. Most peptides (BPC-157, TB-500, ipamorelin, sermorelin, etc.) flow through 503A pharmacies with patient-specific prescriptions.
Does Direct Peptide Sales handle the 503A vs 503B routing?: Yes. We route each product to the correct pharmacy type, your providers prescribe under their license, and every order ships with a COA and chain-of-custody documentation.
What exactly does Direct Peptide Sales do?: We are a referral and introduction service. We verify your business and the states it serves, then introduce you to licensed telehealth prescribers and 503A or 503B pharmacies. You contract directly with them. We do not sell, price, prescribe, compound, bill, or ship any product.
How fast can my practice be introduced to a source?: Timing depends on your business details, states served, and partner fit. DPS does not guarantee an introduction or launch date. The independent partners determine their own onboarding requirements.
What does it cost?: Nothing to apply, and we do not charge practices a fee. Product pricing, account terms, and any minimums are set by the pharmacy or prescriber you contract with, not by us.
Where do the peptides come from and are they verified?: Ask the independent pharmacy to confirm current product status, applicable licenses, and preparation-specific quality documentation. DPS does not test or certify products. The COA library contains illustrative examples, not proof for a future lot.
Who handles prescribing, billing, and shipping?: The licensed prescriber and the pharmacy do. Prescribing is the provider's independent clinical decision, and dispensing, billing, and shipping sit with the pharmacy. We are not part of that transaction.
What if I'm not a licensed clinic?: Non-licensed wellness businesses such as coaches, gyms, studios, and nutrition practices can be introduced to a licensed telehealth prescriber who owns the clinical relationship. You never prescribe, hold, or dispense product.
How do you vet the sources you introduce?: Before contracting, independently verify the source legal identity, licenses for the relevant states, preparation-specific documentation, and written responsibilities. A facility license or COA does not establish that every proposed product may lawfully be prescribed or supplied.
Which states do you serve?: Coverage depends on the states your business serves and the independent partners' licenses. An introduction is not authorization to prescribe or ship into a state.

Request a prescriber or pharmacy introduction

Tell us about your business and the states you serve. You contract directly with the independent partners you choose. There is no fee to apply.

Get Started →